Next Article in Journal
Prevention Strategies in Prostate Cancer
Previous Article in Journal
Multimodal Approaches to High-Risk Prostate Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 17
Issue s2
10.3747/co.v17i0.709
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010

by
H. Quon
and
D. A. Loblaw
*
Department of Radiation Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2010, 17(s2), 38-44; https://doi.org/10.3747/co.v17i0.709
Submission received: 3 June 2010 / Revised: 3 July 2010 / Accepted: 5 August 2010 / Published: 1 September 2010

Abstract

The discovery of androgen deprivation therapy (ADT) has been one of the most important advances in the treatment of prostate cancer. Here, the indications for the use of ADT are reviewed, together with the data supporting each indication. The settings for ADT use include cytoreduction; combined ADT and radiotherapy; pathologic node-positive disease; and recurrent, metastatic, or progressive prostate cancer.
Keywords: androgen antagonists; hormonal anti-neoplastic agents; combined-modality therapy; disease progression; orchiectomy; prostatic neoplasms; radiotherapy; prostatectomy androgen antagonists; hormonal anti-neoplastic agents; combined-modality therapy; disease progression; orchiectomy; prostatic neoplasms; radiotherapy; prostatectomy

Share and Cite

MDPI and ACS Style

Quon, H.; Loblaw, D.A. Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010. Curr. Oncol. 2010, 17, 38-44. https://doi.org/10.3747/co.v17i0.709

AMA Style

Quon H, Loblaw DA. Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010. Current Oncology. 2010; 17(s2):38-44. https://doi.org/10.3747/co.v17i0.709

Chicago/Turabian Style

Quon, H., and D. A. Loblaw. 2010. "Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010" Current Oncology 17, no. s2: 38-44. https://doi.org/10.3747/co.v17i0.709

APA Style

Quon, H., & Loblaw, D. A. (2010). Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010. Current Oncology, 17(s2), 38-44. https://doi.org/10.3747/co.v17i0.709

Article Metrics

Back to TopTop